Contents

Acknowledgments ix

Introduction
  What You Don’t Know About Valuation Will Cost You Money 1

Chapter 1
  Using Facebook, Twitter, and LinkedIn to Explain VC Valuation
  Gains and Losses: How VCs, Angels, Founders, and Employees
  Give Up Investment Cash Flow Every Day 13
  Did Valuation Ignorance Cost ConnectU (and the Winklevosses) $50MM? 14
  An Expert Doesn’t Need a 409A Valuation When He or She Has a Certificate and Basic Math 15
  Valuing Facebook’s Common Stock Compared to Preferred Stock in Minutes 16
  What the Winklevosses Would Have Seen in Any 409A Valuation Report 19
  Deriving a Discount for Lack of Marketability for Valuations 27
  Facebook at $80 Billion Valuation versus Enron at $80 Billion Valuation 35
  Deal Terms, Waterfalls, and the Pre-Money Myth 36
  The Pre-Money Myth 44
  Summary 56

Chapter 2
  Should Venture-Backed Companies Even Consider a DCF Model?:
  Introducing the Life Science Valuation Case: Zogenix 57
  Zogenix: Company Background Summary and Highlights 58
  Leaping Forward Just 20 Months, the Company Files for an IPO 64
  Order of Valuations Presented in This Case 67
CONTENTS

Chapter 3
Valuation Methods versus Allocation Methods Regarding Zogenix 69
  Separating Enterprise Value from the Allocation of That Value 69
  Valuing Total Equity 72
  Using Future Value (FV) and Present Value (PV) to Value Future Cash Flows Today 79
  Summary 82

Chapter 4
Applying the Typical DCF Model to a Venture-Backed Company Hardly Ever Works 85
  The Gordon Growth Model 85
  High Growth Limits the Gordon Growth Model 87
  Dividend Irrelevance and Capital Structure Irrelevance 90
  Using Comparables (Generally Market Multiples) to Generate a Terminal Value 91
  Actual Differences between Angels and VCs versus Perceived Differences 100
  Applying Valuation Methods and Allocation Methods at Inception 102
  Summary 104

Chapter 5
“Enterprise Value” + “Allocation Methods” = Value Destruction: Undervaluing Companies and Overvaluing Employee Options 107
  Most 409A Valuations Undervalue the Company and Simultaneously Overvalue Employee Stock Options 107
  Did Auditors Drive Valuators to Overvalue Employee Stock Options? 109
  Most 409A Enterprise Value Calculations Ignore the “Takeover” Value of Preferred 113
  The Realistic Range of Possibilities Depends on Who the Investors Are 119
  Overstating Returns and Understating Returns on the Same Asset (Simultaneously) 125
  What Happens to Fund IRRs When You Assume Book Value Equals Market Value? 128
  The Real Cost of Fair Value, Fair Market Value, and Enterprise Value 132
  Yahoo! Case 137
Contents

Chapter 6
Why You Should D.O.W.T. (Doubt) Venture Capital Returns—Option Pool Reserve
Unissued Option Pools 159
Value Conclusion Elements Impacted by Option Pool Reserve Assumptions 161
Impact on Parties Relying on Assumptions of VC Investments 176

Chapter 7
If Valuation Can’t Make You Money, Do You Really Need It?: Learning Practical Applications from Kayak.com
Applying Studies to Real-World Cases 186
Important Questions to Ask 213
Summary 223

Chapter 8
Don’t Hate the Appraiser (Blame the Auditor Instead)
Interview with Jeff Faust, AVA 226
Summary 236

Chapter 9
Don’t Blame the Auditors (Blame the Practice Aid Instead): 409A Valuation Professionals Discussing Topic 820 (FAS 157) with VC CFOs
Introduction to the Expert Panelists 238
The Auditor’s Valuation “Bible” 239
SAS101 Tests, PWERMS, and OPMs 240
PWERMS and rNPV/eNPV Models 243
Subjectivity and the PWERM (or “Power”) Method 243
Finding Inputs for the OPM Model 245
Enterprise Values versus Allocations 246
Next Round Pricing and Topic 820 248
Different Ways of Treating Granted, Unvested, and Reserved Options 250
Valuing Warrants in Venture-Backed Companies 252
Quantifying Qualitative Inputs to Value Conclusions for VC-Funded Companies 253
Discounts for Lack of Marketability (DLOM) and Venture-Fund Portfolios 254
Sharespost, SecondMarket as Market Inputs 258
Summary 262
## CONTENTS

<table>
<thead>
<tr>
<th>Chapter 10</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Now That You Understand Venture Capital Valuation, Share It</td>
<td>263</td>
</tr>
</tbody>
</table>

| About the Author  | 269 |
| Index             | 271 |